Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer

Next Previous
Trial Profile

A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Capecitabine
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Voltage study; VOLTAGE-A; VOLTAGE-A1

Most Recent Events

  • 01 Jul 2023 Results (n=25) assessing and efficacy of CRT followed by NIVO +ipilimumab (IPI) combination presented at the 25th World Congress on Gastrointestinal Cancer
  • 06 Jun 2023 Results assessing whether dynamic change of TIL in TME may predict pCR in MSS LARC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 21 Jan 2023 Survival outcomes and functional results of VOLTAGE-A (n=44) presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top